New Oral Psoriasis Drug Icotrokinra Outperforms Existing Treatment in Phase 3 Trials
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Autoimmune diseases, immune modulation, inflammation, and self-tolerance
219 articles
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Clinical trial results for oral icotrokinra in treating plaque psoriasis across adult and adolescent patients published in NEJM.
New research reveals atopic dermatitis has multiple biological subtypes, each requiring personalized treatment approaches.
New spatial multiomics study maps cellular interactions in systemic sclerosis, revealing fibroblast-macrophage dynamics.
New research reveals how IL-35 therapy prevents neutrophil trap formation, offering hope for cigarette smoke-worsened asthma.
Review examines immunosuppressive drugs like cyclosporine and tacrolimus, highlighting new applications and safety management strategies.
New research reveals how IGF2BP3 protein promotes inflammation and tissue damage in rheumatoid arthritis through RNA modifications.
Expert commentary on pemphigus foliaceus, a rare autoimmune blistering disease affecting skin health and immune function.
Delphi study of 166 Italian neurologists establishes guidelines for individualized MS therapy based on patient needs and drug characteristics.
65 neurologists from 54 Italian MS centers agree on when and how to use high-efficacy therapies to prevent irreversible disability.
New research reveals how necroptosis activates immune pathways, offering targets for inflammatory bowel disease treatment.
Comprehensive review explores how combining genomics, proteomics, and metabolomics advances psoriasis understanding and treatment.